ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Expanded Access to ABBV-8E12

Conditions: Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)

First Posted Date: 2018-11-16

Last Posted Date: 2019-08-20

Lead Sponsor: AbbVie

Registration Number: NCT03744546

An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs

Completed

Conditions: Hepatitis C

First Posted Date: 2018-11-14

Last Posted Date: 2024-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 3134

Registration Number: NCT03740230

Locations: 🇰🇷
Kwangju Christian Hospital /ID# 210623, Gwangju, Jeonranamdo, Korea, Republic of
🇰🇷
SMG-SNU Boramae Medical Center /ID# 210610, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷
Wonkwang University Hospital /Id# 210620, Iksan, Jeonrabugdo, Korea, Republic of

and more 58 locations

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Cariprazine

First Posted Date: 2018-11-13

Last Posted Date: 2022-10-25

Lead Sponsor: AbbVie

Target Recruit Count: 759

Registration Number: NCT03738215

Locations: 🇺🇸
Lehigh Center for Clinical Research /ID# 236702, Allentown, Pennsylvania, United States
🇺🇸
Hassman Research Institute /ID# 237501, Berlin, New Jersey, United States
🇺🇸
Psych Atlanta /ID# 235835, Marietta, Georgia, United States

and more 122 locations

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis (MS)

Interventions: Drug: placebo
Drug: elezanumab

First Posted Date: 2018-11-13

Last Posted Date: 2023-12-21

Lead Sponsor: AbbVie

Target Recruit Count: 123

Registration Number: NCT03737812

Locations: 🇺🇸
Central Texas Neurology Consul /ID# 203108, Round Rock, Texas, United States
🇨🇦
Montreal Neurological Institut /ID# 203868, Montreal, Quebec, Canada
🇨🇦
Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 203869, Montreal, Quebec, Canada

and more 34 locations

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Upadacitinib
Biological: Dupilumab
Drug: Placebo to upadacitinib
Drug: Placebo to dupilumab

First Posted Date: 2018-11-13

Last Posted Date: 2024-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 673

Registration Number: NCT03738397

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine /ID# 208680, Chicago, Illinois, United States
🇺🇸
Medical Dermatology Associates of Chicago /ID# 210265, Chicago, Illinois, United States
🇺🇸
Miami Dermatology and Laser Institute /ID# 212938, Miami, Florida, United States

and more 156 locations

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Cariprazine
Drug: Antidepressant Therapy (ADT)

First Posted Date: 2018-11-13

Last Posted Date: 2022-09-21

Lead Sponsor: AbbVie

Target Recruit Count: 752

Registration Number: NCT03739203

Locations: 🇺🇸
Global Clinical Trials /ID# 235059, Costa Mesa, California, United States
🇺🇸
Institute for Advanced Medical Research /ID# 234992, Atlanta, Georgia, United States
🇺🇸
International Research Associates, LLC /ID# 237410, Miami, Florida, United States

and more 109 locations

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis (MS)

Interventions: Drug: elezanumab
Drug: placebo

First Posted Date: 2018-11-13

Last Posted Date: 2023-12-22

Lead Sponsor: AbbVie

Target Recruit Count: 208

Registration Number: NCT03737851

Locations: 🇺🇸
Duplicate_Parexel International /ID# 204273, Baltimore, Maryland, United States
🇺🇸
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249, Berkeley, California, United States
🇺🇸
UC Irvine Health /ID# 205728, Irvine, California, United States

and more 46 locations

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Phase 1

Active, not recruiting

Conditions: Juvenile Idiopathic Arthritis (JIA)

Interventions: Drug: Upadacitinib

First Posted Date: 2018-10-30

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 122

Registration Number: NCT03725007

Locations: 🇺🇸
Cincinnati Childrens Hospital Medical Center /ID# 209697, Cincinnati, Ohio, United States
🇵🇷
Centro de Reumatologia Pediatrico de Puerto Rico /Id# 204406, Bayamon, Puerto Rico
🇵🇷
Mindful Medical Research /ID# 204488, San Juan, Puerto Rico

and more 32 locations

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Phase 3

Active, not recruiting

Conditions: Giant Cell Arteritis (GCA)

Interventions: Drug: Upadacitinib
Drug: Corticosteroid (CS)
Other: Placebo

First Posted Date: 2018-10-30

Last Posted Date: 2024-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 429

Registration Number: NCT03725202

Locations: 🇺🇸
University of Vermont Medical Center /ID# 211179, Burlington, Vermont, United States
🇺🇸
Omega Research Group /ID# 201903, Orlando, Florida, United States
🇺🇸
IRIS Research and Development, LLC /ID# 169406, Plantation, Florida, United States

and more 169 locations

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Tilavonemab

First Posted Date: 2018-10-19

Last Posted Date: 2022-09-22

Lead Sponsor: AbbVie

Target Recruit Count: 364

Registration Number: NCT03712787

Locations: 🇦🇺
Griffith University /ID# 204905, Southport, Queensland, Australia
🇪🇸
Hospital Clinic de Barcelona /ID# 204519, Barcelona, Spain
🇸🇪
Karolinska University Hospital Huddinge /ID# 203900, Stockholm, Stockholms Lan, Sweden

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy